Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M. Khanani, Francisco J. Rodríguez, Peter K. Kaiser et al.|The Lancet|2023Cited by 343